Therapeutic advances in psychopharmacology · 2025
Ketamine dosing formula in treatment-resistant bipolar depression.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kwaśny Aleksander, Jerzy Cubała Wiesław, Wilkowska Alina
Аннотация
BACKGROUND: Intravenous ketamine is effective in treatment-resistant bipolar depression (TRBD) with dosing typically based on actual body weight (ABW).
OBJECTIVE: This study examined whether alternative normalization formulas are associated with treatment response.
DESIGN: A retrospective exploratory analysis of a naturalistic registry for short-term ketamine use.
METHODS: A total of 22 TRBD inpatients received short-term intravenous ketamine. Doses were recalculated using the Boer and Devine formulas for lean body mass (LBM) and ideal body weight (IBW), and the Mosteller formula for body surface area (BSA). Calculated doses were compared with ABW dosing in responders and nonresponders.
RESULTS: Using the Mosteller formula, BSA-normalized doses ranged from 17.63-23.09 mg/m2 in nonresponders and 15.73-23.89 mg/m2 in responders. LBM- and IBW-based recalculations at 0.5 mg/kg yielded lower relative doses, particularly among nonresponders, suggesting potential underdosing.
CONCLUSION: These preliminary findings do not support alternative dosing formulas over ABW, but replication in larger controlled studies is warranted.
OBJECTIVE: This study examined whether alternative normalization formulas are associated with treatment response.
DESIGN: A retrospective exploratory analysis of a naturalistic registry for short-term ketamine use.
METHODS: A total of 22 TRBD inpatients received short-term intravenous ketamine. Doses were recalculated using the Boer and Devine formulas for lean body mass (LBM) and ideal body weight (IBW), and the Mosteller formula for body surface area (BSA). Calculated doses were compared with ABW dosing in responders and nonresponders.
RESULTS: Using the Mosteller formula, BSA-normalized doses ranged from 17.63-23.09 mg/m2 in nonresponders and 15.73-23.89 mg/m2 in responders. LBM- and IBW-based recalculations at 0.5 mg/kg yielded lower relative doses, particularly among nonresponders, suggesting potential underdosing.
CONCLUSION: These preliminary findings do not support alternative dosing formulas over ABW, but replication in larger controlled studies is warranted.